A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy
Aohua Deng, Renming Fan, Yongrui Hai, Junyan Zhuang, Bingjie Zhang, Xintong Lu, Wenhui Wang, Li Luo, Ge Bai, Lei Liang, Le Yang, Ming Zhao, Gaofei Wei
Abstract
By targeting TREM2 and activating the STING signaling pathway in TAMs, prodrug GB2 exhibits excellent anti-tumor efficacy and immune-activating capacity in the mouse colon cancer model.
Topics & Concepts
ProdrugStingColorectal cancerImmunotherapyAgonistCancer immunotherapyMedicineCancer researchMacrophageCancerPharmacologyInternal medicineOncologyChemistryReceptorPhysicsThermodynamicsIn vitroBiochemistryinterferon and immune responsesCancer Mechanisms and TherapyImmune cells in cancer